Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock

- December 6th, 2018

Momenta Pharmaceuticals (Nasdaq:MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced that it is commencing an underwritten registered public offering of $150,000,000 of shares of its common stock. As quoted in the press release: Momenta also expects to grant the underwriter … Continued

Momenta Pharmaceuticals (Nasdaq:MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced that it is commencing an underwritten registered public offering of $150,000,000 of shares of its common stock.

As quoted in the press release:

Momenta also expects to grant the underwriter of the offering an option to purchase up to an additional $22,500,000 of shares of its common stock, exercisable for 30 days. All of the shares in the proposed offering are to be sold by Momenta.

Goldman Sachs & Co. LLC is acting as sole book-running manager for the offering.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 that was initially filed with the U.S. Securities and Exchange Commission (SEC) on February 29, 2016. A preliminary prospectus supplement describing the terms of the offering will be filed with the SEC and will form a part of the effective registration statement.

Click here to read the full press release.

Find out what experts are saying about the future of cannabis


Read our new report today

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Tags

Leave a Reply

Your email address will not be published. Required fields are marked *